[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skeletal-muscle\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skeletal-muscle":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,72,97,118,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":44,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100629969","impact-of-training-load-on-the-gut-microbiome-and-its-relation-to-exercise-performance-muscle-phenotype-and-markers-of-overreaching-in-healthy-men-100629969",false,"NCT07481578","Impact of Training Load on the Gut miCrobiome And Its Relation to exeRcise Performance, mUscle Phenotype, and markerS of Overreaching in Healthy Men","ICARUS: Impact of Training Load on the Gut Microbiome and Its Relation to Exercise Performance, Muscle Phenotype, and Markers of Overreaching in Healthy Men: Phase A - Human Trial","ICARUS","Inclusion criteria:\n\n* Males between 18 and 45 years old.\n* Recreationally active individuals, with a weekly exercise training volume between one and six hours per week.\n* Good health status confirmed by a sport medical screening, which includes a sport medical questionnaire and resting electrocardiogram.\n* Body Mass Index (BMI) between 18.5 and 27.5 kg\u002Fm².\n* Masters the Dutch language.\n\nExclusion criteria:\n\n* Engagement in strenuous competitive sports one month prior to or during the study intervention.\n* Medication and vaccination: Pro- or antibiotic treatment during the past three months, non-steroidal anti-inflammatory drugs (NSAIDs) or cholestyramine during the past month, drugs interfering with intestinal permeability (e.g., prokinetics, laxatives, lubiprostone, loperamide, anti-spasmodics, linaclotide, proton pump inhibitors) during the past month. Vaccinations within one month prior to or during the study intervention.\n* Blood donations within three months or plasma donation within one month prior to or during the study intervention.\n* Inflammatory bowel disease (Crohn or colitis ulcerosa) or celiac disease.\n* Diagnosed irritable bowel syndrome.\n* Intake of any performance-enhancing medication or nutritional supplements known to modulate the gut microbiome in the two months prior to or during the study.\n* Substance abuse, including alcohol consumption of more than three units\u002Fday (weekly average).\n* Any injury or pathology considered a contraindication for performing physical exercise, as determined by the medical doctor overseeing the preparticipation medical screening.\n* No access to smartphone and\u002For computer with internet access.\n* No willingness to use the Polar Flow app and MijnEetmeter to collect physical activity, heart rate, sleep, and food intake data.\n* Concomitant participation in another interventional trial, without approval from the research team.\n* Any other reasons considered by the research team that the participant will not complete the study.",true,"MALE","18 Years","45 Years",{"count":22,"type":23},45,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this study is to learn how different amounts of supervised indoor cycling training change gut health (gut bacteria, the substances gut bacteria make, and the gut barrier integrity), and how these changes relate to changes in fitness, muscle health, and signs of doing too much training (a state called 'overreaching'). The study includes healthy, recreationally active men aged 18 to 45 years.\n\nThe primary questions, for which the study is powered (sufficient participants included), are:\n\n1. Does moderate load training change blood and faecal levels of butyrate (a short-chain fatty acid made by gut bacteria) after eight weeks compared with a control group?\n2. Compared to moderate load training, do higher training loads lead to different responses in blood and faecal levels of butyrate?\n\nResearchers will compare:\n\n* A control group that does not complete structured training;\n* A moderate-load training group that completes eight weeks of supervised cycling (4x\u002Fweek);\n* A high-load training group that completes four weeks of moderate-load training followed by four weeks of higher training load (twice the number of training sessions).\n\nParticipants will:\n\n* Be randomly assigned to one of the three groups;\n* Complete 8 weeks of supervised indoor cycling sessions if assigned to a training group;\n* Complete four study assessment periods (baseline, after week four, after week eight, and after a short taper (rest period);\n* Provide blood, stool, skeletal muscle, urine, saliva, and breath samples during the assessment periods;\n* Complete fitness and performance tests and questionnaires during the assessment periods.",[29,30,31,32,33,34,35,36,37,38,39,40,41,42,43],"Exercise","Overreaching","Butyrate","Gut Microbiome","Exercise Performance","Skeletal Muscle","Glucose Tolerance","Hormones","Vascular Health","Muscle Adaptation","Physical Fitness","Heart Rate Variability (HRV)","Anthropometric Measurements","Metabolic Health","Food Intake",[45,46,47,48,49,50,51,52,30,53,54,55,40,56,57,58],"Exercise training","Training load","Overload training","Fecal butyrate","Gut health","Exercise performance","Muscle phenotype","Physical fitness","Glucometabolic health","Vascular health","Muscle adaptation","Anthropometrics","Metabolic health","Food intake","RECRUITING","2026-03-16",{"date":62,"type":63},"2026-03-19","ACTUAL",{"date":65,"type":63},"2024-10-07",{"date":67,"type":23},"2027-05-31",{"name":69,"class":70},"Stefan De Smet","OTHER",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":24,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":71},"100599977","glucagon-like-peptide-1-glp-1-receptor-agonist-therapy-and-exercise-training-in-people-with-obesity-100599977","NCT07091500","Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity","Effect of GLP-1 Receptor Agonist Therapy With and Without Exercise Training on Muscle Mass and Physical Function in People With Obesity","Inclusion Criteria:\n\n* i) obesity (Body Mass Index ≥ 30 kg\u002Fm2)\n* ii) decreased physical function (Modified Physical Performance Test score 17 to 31)\n* iii) approval of their primary physician to participate in this study.\n\nExclusion Criteria:\n\n* i) unstable weight (\\>4% change during the last 2 months before entering the study)\n* ii) ≥150 min per week of structured exercise (e.g., jogging, activities that cause heavy breathing and sweating)\n* iii) diabetes\n* iv) significant cardiopulmonary disease (heart failure, angina, uncontrolled hypertension, chronic obstructive pulmonary disease) or other organ dysfunction (e.g., renal insufficiency \\[eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2\\])\n* v) therapy with a GLP-1 or other weight loss medications\n* vi) clinically significant gastric emptying abnormality or chronically take drugs that directly affect gastrointestinal motility\n* vii) history of chronic or acute pancreatitis\n* viii) thyroid-stimulating hormone (TSH) \\>1.5X the upper limit of normal (patients receiving treatment for hypothyroidism may be included provided their thyroid hormone replacement dose has been stable for at least 3 months)\n* ix) history of significantly active or unstable Major Depressive Disorder or other severe psychiatric disorder (e.g. schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 months that would interfere with study participation\n* x) acute or chronic hepatitis, or other liver disease other than Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD)\n* xi) family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2\n* xii) history of active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal- or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years\n* xiii) tobacco use, excessive alcohol intake (≥3 drinks\u002Fday for men and ≥2 drinks\u002Fday for women) or active substance abuse with illegal drugs by self-report, or regular marijuana use within 3 months of enrollment and unwilling to abstain from marijuana during the trial\n* xiv) Use of medications that are known to affect the study outcome measures or increase the risk of study procedures and that cannot be temporarily discontinued for this study\n* xv) have had bariatric surgery or plan to have endoscopic or bariatric surgery therapy for obesity\n* xvi) anemia (Hgb \\\u003C10 g\u002FdL)\n* xvii) Conditions that render subject unable to complete all testing procedures (e.g., severe ambulatory impairments, limb amputations, or metal implants that interfere with imaging procedures; coagulation disorders)\n* xii) history of seizure disorder\n* xix) Female who is pregnant, breast-feeding or intends to become pregnant\n* xx) allergy or hypersensitivity to GLP-1 RA medications\n* xxi) unable to grant voluntary informed consent\n* xxii) unable or unwilling to follow the study protocol or who, for any reason, the research team considers the participant is not an appropriate candidate for the study","ALL","50 Years","75 Years",{"count":83,"type":23},40,[26],"The use of glucagon-like peptide receptor agonists (GLP-1 RAs) may have clinically important effects on skeletal muscle mass (SMM), and physical function. The effects of exercise training in conjunction with GLP-1 RA therapy on these outcomes has not been studied. Additionally, most people treated with GLP-1-based weight loss medications stop taking these medications within 1 year of initiating treatment. This is an important clinical concern because weight regain can occur after weight loss pharmacotherapy is stopped and the impact of stopping GLP-1 RA therapy on physical and metabolic function has not been studied.\n\nIn this study, the investigators will conduct a 2-year randomized clinical trial to evaluate body composition, muscle physical and metabolic function, and muscle strength in response to GLP-1 RA therapy, with or without exercise training, and subsequent treatment cessation on muscle-related outcomes.",[87,34],"Obesity","2025-09-22",{"date":90,"type":63},"2025-09-23",{"date":92,"type":63},"2025-08-11",{"date":94,"type":23},"2029-08-01",{"name":96,"class":70},"Washington University School of Medicine",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":17,"sex":79,"minAge":19,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":24,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":71},"100568171","skeletal-muscle-myokine-response-to-acute-eccentric-exercise-100568171","NCT06677749","Skeletal Muscle Myokine Response to Acute Eccentric Exercise","Inclusion Criteria:\n\n* 18-35 years old\n* healthy\n* recreationally active (\\>\u002F= 150 minutes of moderate to vigorous physical activity per week for at least the past three months)\n\nExclusion Criteria:\n\n* \"yes\" answer to the Get Active Questionnaire which screens for health conditions that may affect exercise ability","35 Years",{"count":105,"type":23},12,[26],"The purpose of this study is to evaluate the acute local skeletal muscle inflammatory response to thigh muscle (quadriceps) eccentric muscle actions. Eccentric muscle actions occur when the muscle is lengthening as it contracts. This is a pilot project to assess the degree of inflammatory biomarkers, called myokines, that are released locally in skeletal muscle tissue after an acute bout of resistance-exercise using a resistance-exercise machine called an isokinetic dynamometer.",[34],"2024-11-04",{"date":111,"type":63},"2024-11-07",{"date":113,"type":23},"2024-11-15",{"date":115,"type":23},"2025-11-01",{"name":117,"class":70},"University of Manitoba",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":79,"minAge":125,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":24,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":71},"100567337","skeletal-muscle-mass-changes-on-images-for-prediction-of-prognosis-after-exercise-training-in-hnscc-patients-100567337","NCT06666881","Skeletal Muscle Mass Changes on Images for Prediction of Prognosis After Exercise Training in HNSCC Patients","(Health Promotion) Skeletal Muscle Mass Changes on Images for Prediction of Prognosis After Exercise Training in Head and Neck Cancer Patients","Inclusion Criteria:\n\n1. Age ≥20\n2. Pathology:Squamous cell carcinoma\n3. Need CCRT treatment\n4. ECOG PS\\\u003C2\n5. Agree with blood drawing, exercise training, and all the procedures in the trial.\n\nExclusion Criteria:\n\n1. ECOG PS≥2\n2. Participants with intolerance basic exercise training, or without CCRT treatment\n3. Mental illness or any medical illness or concurrent illness that may be aggravated by exercise training or unmanageable\n4. Any medical condition that unsuitable for exercise training\n5. refure to do the trial procedures: exercise training, blood drawing and all the procedures in the trial.\n6. can't get the data for the whole-body computed tomography","20 Years","80 Years",{"count":128,"type":23},60,[26],"This project adopts a prospective study design. It is scheduled to enroll 60 participants diagnosed with Head and Neck cancer in this hospital, of which 30 are in the experimental group and 30 are in the control group. The purpose of this research is to analyze the skeletal muscle mass changes on images in Head and Neck cancer patients after exercise training and the association with systemic inflammatory markers. Investigators would like to know whether these images and biomarkers predict the prognosis of Head and Neck cancer. Subjects enrolled in the trial will receive 36 times of exercise training after concurrent chemoradiotherapy. Before and after the completion of exercise training, investigators will arrange (1) dual energy X-ray absorptiometry (DXA) to measure the whole-body skeletal muscle mass and appendicular skeletal muscle mass and (2) blood tests for markers of systemic inflammation. In addition to DXA, computed tomography (CT) is another image modality for skeletal muscle mass evaluation. Positron emission tomography - CT or whole-body CT for cancer staging are considered as baseline studies. The routine follow-up CT images are used to analyze the changes after exercise training. If magnetic resonance imaging is also performed during the follow-up period, images will also be collected and assessed as an alternative.If the experimental group can maintain or even improve skeletal muscle mass and can be reflected in blood tests and prognosis, the result may be able to apply on cancer treatment and disease followup.",[132,34],"Head and Neck Cancer",[134,135,136,137],"exercise training","dual energy X-ray absorptiometry","sarcopenia","head and neck cancer","2024-10-29",{"date":140,"type":63},"2024-10-31",{"date":142,"type":63},"2023-06-06",{"date":144,"type":23},"2027-09-30",{"name":146,"class":70},"Chang Gung Memorial Hospital",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":17,"sex":79,"minAge":19,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":24,"phases":156,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":71},"100552615","the-effects-of-l-arginine-supplementation-on-anaerobic-exercise-performance-100552615","NCT06475391","The Effects of L-arginine Supplementation on Anaerobic Exercise Performance","Inclusion Criteria:\n\n* Recreationally physically active individuals will be recruited for the study. In this context it means all participants perform 1-hour of exercise per day over 3-days per week at a minimum for 1-month. All participants will be between the ages of 18-39 years of age.\n\nExclusion Criteria:\n\n* Exclusion criteria for the study includes: 1) smokers; 2) unhealthy (have cardiovascular, metabolic, neurological, or psychological disease); 3) taking medication for any condition; 4) any known allergy to the supplements of interest (L-arginine or placebo \\[dextrose\\]).","39 Years",{"count":155,"type":23},20,[26],"The purpose of this study is to evaluate if acute ingestion of L-arginine will enhance anaerobic exercise performance in young, healthy, and recreationally active adults.",[34,159],"Human Performance","2024-06-25",{"date":162,"type":63},"2024-06-26",{"date":164,"type":63},"2024-06-14",{"date":166,"type":23},"2024-12-31",{"name":117,"class":70}]